浏览全部资源
扫码关注微信
1.湖南中医药大学,长沙 410208
2.湖南中医药大学 第二附属医院,长沙 410005
Received:30 November 2021,
Published Online:20 July 2022,
Published:05 November 2022
移动端阅览
俞赟丰,上官雪丽,李新.基于HGF/C-Met信号通路探讨乌梅丸对寒热错杂证Lewis肺癌小鼠的抑癌作用及机制[J].中国实验方剂学杂志,2022,28(21):32-41.
YU Yunfeng,SHANGGUAN Xueli,LI Xin.Effect and Mechanism of Wumeiwan Against Lewis Lung Cancer in Mice with Syndrome of Cold and Heat in Complexity Based on HGF/C-Met Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(21):32-41.
俞赟丰,上官雪丽,李新.基于HGF/C-Met信号通路探讨乌梅丸对寒热错杂证Lewis肺癌小鼠的抑癌作用及机制[J].中国实验方剂学杂志,2022,28(21):32-41. DOI: 10.13422/j.cnki.syfjx.202201722.
YU Yunfeng,SHANGGUAN Xueli,LI Xin.Effect and Mechanism of Wumeiwan Against Lewis Lung Cancer in Mice with Syndrome of Cold and Heat in Complexity Based on HGF/C-Met Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(21):32-41. DOI: 10.13422/j.cnki.syfjx.202201722.
目的
2
基于肝细胞生长因子及其受体(HGF/C-Met)信号通路探讨乌梅丸对寒热错杂证Lewis肺癌小鼠的抑癌效果及作用机制。
方法
2
将20只健康雄性小鼠分为正常组、模型组、顺铂组和乌梅丸组,每组5只。通过丙硫氧嘧啶+知母石膏水煎液+番泻叶灌胃、冰水游泳与干酵母混悬液皮下注射,联合Lewis细胞悬液右侧腋窝皮下注射的方式制备寒热错杂证Lewis肺癌小鼠模型。模型制备完成后,顺铂组予以4.0 mg·kg
-1
顺铂腹腔注射,乌梅丸组予以12.5 mL·kg
-1
乌梅丸灌胃,模型组予以等体积蒸馏水灌胃,连续6周。取材检验,测量和计算瘤质量、瘤体积、抑癌率和抑制肺癌转移率,采用苏木素-伊红(HE)染色观察肺癌组织病理学形态,采用免疫组化法分析肿瘤组织生长状态,采用实时荧光定量聚合酶链式反应(Real-time PCR)检测HGF、C-Met mRNA表达,采用蛋白免疫印迹法(Western blot)检测HGF、C-Met、存活素(Survivin)和X连锁凋亡抑制蛋白(XIAP)的蛋白表达。
结果
2
与正常组比较,模型组HGF、C-Met mRNA表达显著升高(
P
<
0.01),HGF、C-Met、Survivin和XIAP的蛋白表达显著升高(
P
<
0.01)。与模型组比较,乌梅丸组的阳性细胞比率、阳性细胞密度、阳性评分降低(
P
<
0.05),组织化学评分、瘤质量、瘤体积显著降低(
P
<
0.01),HGF、C-Met mRNA表达显著降低(
P
<
0.01),HGF、C-Met、Survivin和XIAP的蛋白表达显著降低(
P
<
0.01)。与模型组比较,顺铂组的阳性细胞率、阳性细胞密度明显降低(
P
<
0.05),阳性评分、瘤质量、瘤体积显著降低(
P
<
0.01),HGF、C-Met mRNA表达显著降低(
P
<
0.01),HGF、C-Met、Survivin、XIAP蛋白表达显著降低(
P
<
0.01);组织化学评分相当,差异无统计学意义。与顺铂组比较,乌梅丸组HGF mRNA表达升高(
P
<
0.01);阳性细胞率、阳性细胞密度、组织化学评分、阳性评分、瘤质量、瘤体积相当,C-Met mRNA表达及HGF、C-Met、Survivin、XIAP蛋白表达相当,差异均无统计学意义。
结论
2
乌梅丸能够通过抑制HGF/C-Met信号通路减缓寒热错杂证Lewis肺癌小鼠的肺癌进展。
Objective
2
To investigate the effect and mechanism of Wumeiwan against Lewis lung cancer in mice with syndrome of cold and heat in complexity based on hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/C-Met) signaling pathway.
Method
2
Twenty healthy male mice were classified into blank group, model group (equivalent volume of distilled water,
ig
), cisplatin group (4.0 mg·kg
-1
cisplatin,
ip
), and Wumeiwan group (12.5 mL·kg
-1
Wumeiwan,
ig
), with 5 in each group. Lewis lung cancer with the syndrome of cold and heat in complexity was induced in mice except the blank group by gavage of propylthiouracil, Zhimu Shigaotang, and Fanxieye, ice-water swimming, and subcutaneous injection of dry yeast suspension and Lewis cell suspension under the right armpit. After modeling, administration began and lasted 6 weeks. After the experiment, the tumor weight, tumor volume, tumor inhibition rate, and lung cancer metastasis-inhibiting proportion were measured and calculated. The pathological morphology of lung tissue was observed based on hematoxylin and eosin (HE) staining. The growth state of tumor tissue was analyzed by immunohistochemistry. The mRNA expression of HGF and C-Met was detected by Real-time polymerase chain reaction (PCR), and the protein expressions of HGF, C-Met, survivin, and X-linked inhibitor of apoptosis protein (XIAP) by Western blot.
Result
2
Compared with the blank group, the model group showed high mRNA expression of HGF and C-Met and protein expression of HGF, C-Met, surviving, and XIAP (
P
<
0.01). Compared with the model group, Wumeiwan group displayed low proportion of positive cells, positive cell density, positive score (
P
<
0.05), histochemical score, tumor weight, tumor volume (
P
<
0.01), mRNA expression of HGF and C-Met (
P
<
0.01), and protein expression of HGF, C-Met, surviving, and XIAP (
P
<
0.01). Compared with the model group, the cisplatin group displayed decrease in the proportion of positive cells, density of positive cells (
P
<
0.05), positive score, tumor weight, tumor volume (
P
<
0.01), mRNA expression of HGF and C-Met (
P
<
0.01), and protein expression of HGF, C-Met, surviving, and XIAP (
P
<
0.01), and insignificant variation in the histochemical score. Wumeiwan group had high mRNA expression of HGF (
P
<
0.01), and insignificant variation in the proportion of positive cells, positive cell density, histochemical score, positive score, tumor weight, tumor volume, mRNA expression of C-Met, and protein expression of HGF, C-Met, surviving, and XIAP.
Conclusion
2
Wumeiwan can slow down the progression of Lewis lung cancer in mice with syndrome of cold and heat I complexicity by inhibiting HGF/C-Met signaling pathway.
ZHANG Y , SUN Y , JIA Y , et al . α 5-nAChR and survivin: Two potential biological targets in lung adenocarcinoma [J]. J Cell Physiol , 2021 , 236 ( 3 ): 1787 - 1797 .
BRAY F , FERLAY J , SOERJOMATARAM I , et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2018 , 68 ( 6 ): 394 - 424 .
MAO Y , YANG D , HE J , et al . Epidemiology of lung cancer [J]. Surg Oncol Clin N Am , 2016 , 25 ( 3 ): 439 - 45 .
SCHWARTZ A G , COTE M L . Epidemiology of lung cancer [J]. Adv Exp Med Biol , 2016 , 893 : 21 - 41 .
DIDKOWSKA J , WOJCIECHOWSKA U , MAŃCZUK M , et al . Lung cancer epidemiology: Contemporary and future challenges worldwide [J]. Ann Transl Med , 2016 , 4 ( 8 ): 150 - 160 .
GOLDSTRAW P , CHANSKY K , CROWLEY J , et al . The IASLC lung cancer staging project: Proposals for revision of the TNM Stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer [J]. J Thorac Oncol , 2016 , 11 ( 1 ): 39 - 51 .
DUMA N , SANTANA-DAVILA R , MOLINA J R . Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment [J]. Mayo Clin Proc , 2019 , 94 ( 8 ): 1623 - 1640 .
BEZZECCHI E , RONZIO M , SEMEGHINI V , et al . NF-YA overexpression in lung cancer: LUAD [J]. Genes (Basel) , 2020 , 11 ( 2 ): 198 - 214 .
OSMANI L , ASKIN F , GABRIELSON E , et al . Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy [J]. Semin Cancer Biol , 2018 , 52 ( 1 ): 103 - 109 .
NAGASAKA M , GADGEEL S M . Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer [J]. Expert Rev Anticancer Ther , 2018 , 18 ( 1 ): 63 - 70 .
GROOME P A , BOLEJACK V , CROWLEY J J , et al . The IASLC lung cancer staging project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J]. J Thorac Oncol , 2007 , 2 ( 8 ): 694 - 705 .
MIRANDA O , FAROOQUI M , SIEGFRIED J M . Status of agents targeting the HGF/C-Met axis in lung cancer [J]. Cancers (Basel) , 2018 , 10 ( 9 ): 280 - 297 .
LIANG H , WANG M . Metoncogene in non-small cell lung cancer: Mechanism of Met dysregulation and agents targeting the HGF/C-Met axis [J]. Onco Targets Ther , 2020 , 25 ( 13 ): 2491 - 2510 .
罗秋月 , 周莎 , 熊绍权 , 等 . 从乌梅丸主厥阴探析晚期肺癌 [J]. 辽宁中医杂志 , 2019 , 46 ( 5 ): 979 - 981 .
周曼丽 , 俞赟丰 , 罗晓欣 , 等 . 基于LC-MS技术的养心通脉方干预冠心病血瘀证的代谢组学分析 [J]. 中国实验方剂学杂志 , 2021 , 27 ( 22 ): 139 - 146 .
宋捷民 , 钱旭武 , 滕晔 , 等 . “寒热并见”大鼠模型的建立及评价 [J]. 中国中医基础医学杂志 , 2014 , 20 ( 1 ): 39 - 41 .
潘俊杰 , 陈芳 , 杨宏宽 , 等 . 清肺解毒汤对小鼠Lewis肺癌皮下移植瘤生长及肿瘤微环境免疫抑制的影响 [J]. 中华中医药杂志 , 2020 , 35 ( 11 ): 5752 - 5755 .
项磊 , 苏明君 , 马志超 , 等 . 扶正抑瘤汤对肺癌荷瘤小鼠肿瘤生长、免疫微环境的影响 [J]. 世界中西医结合杂志 , 2021 , 16 ( 8 ): 1447 - 1452 .
闫曙光 , 惠毅 , 李京涛 . 乌梅丸方对溃疡性结肠炎大鼠结肠上皮细胞凋亡的影响 [J]. 中国中医基础医学杂志 , 2016 , 22 ( 6 ): 771 - 773 .
周曼丽 , 俞赟丰 , 罗晓欣 , 等 . 线粒体动力学介导冠心病血瘀证心肌能量代谢的研究 [J]. 中国实验方剂学杂志 , 2021 , 27 ( 21 ): 80 - 90 .
汪珺 , 周慧敏 , 陈赛里 , 等 . 李家庚辨治肺癌验案举隅 [J]. 湖北中医药大学学报 , 2019 , 21 ( 5 ): 111 - 113 .
王熙 , 张莹雯 . 乌梅丸含药血清对胰腺癌细胞增殖及糖酵解的影响 [J]. 中国药师 , 2021 , 24 ( 9 ): 1601 - 1605 .
张然 , 李素娟 , 陈正彦 , 等 . 基于Wnt通路加味乌梅丸对结肠癌的抑制机制 [J]. 世界中医药 , 2018 , 13 ( 8 ): 1972 - 1975 .
BIRCHMEIER C , BIRCHMEIER W , GHERARDI E , et al . Met, metastasis, motility and more [J]. Nat Rev Mol Cell Biol , 2003 , 4 ( 12 ): 915 - 925 .
FIRTINA K Z , KOC D , ISCAN E , et al . Elevated hepatocyte growth factor expression as an autocrine C-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells [J]. Cancer Sci , 2016 , 107 ( 4 ): 407 - 416 .
DU M , WANG J , CHEN H , et al . MicroRNA-200a suppresses migration and invasion and enhances the radiosensitivity of NSCLC cells by inhibiting the HGF/C-Met signaling pathway [J]. Oncol Rep , 2019 , 41 ( 3 ): 1497 - 1508 .
BHARDWAJ V , CASCONE T , CORTEZ M A , et al . Modulation of C-Met signaling and cellular sensitivity to radiation: Potential implications for therapy [J]. Cancer , 2013 , 119 ( 10 ): 1768 - 1775 .
RAGHAV K P , WANG W , LIU S , et al . cMET and phospho-cMET protein levels in breast cancers and survival outcomes [J]. Clin Cancer Res , 2012 , 18 ( 8 ): 2269 - 2277 .
ABOUNADER R , LATERRA J . Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis [J]. Neuro Oncol , 2005 , 7 ( 4 ): 436 - 451 .
KERMORGANT S , APARICIO T , DESSIRIER V , et al . Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement [J]. Carcinogenesis , 2001 , 22 ( 7 ): 1035 - 1042 .
SIEGFRIED J M , WEISSFELD L A , SINGH-KAW P , et al . Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer [J]. Cancer Res , 1997 , 57 ( 3 ): 433 - 439 .
刘传苗 , 刘明珠 , 黄艳平 , 等 . 靶向人C-Met蛋白单链抗体的制备及其对肺腺癌A549细胞的杀伤作用 [J]. 细胞与分子免疫学杂志 , 2018 , 34 ( 5 ): 401 - 407 .
沈东 , 王维 . 紫草素对HGF诱导的人肺癌细胞上皮-间充质转化的逆转作用 [J]. 中国病理生理杂志 , 2018 , 34 ( 9 ): 1622 - 1626 .
鄢丽敏 , 张志勇 , 闫继东 , 等 . C-Met基因调控肺腺癌A549细胞放射敏感性 [J]. 临床与实验病理学杂志 , 2018 , 34 ( 8 ): 865 - 870 .
CASCONE T , XU L , LIN H Y , et al . The HGF/c-Met pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer [J]. Clin Cancer Res , 2017 , 23 ( 18 ): 5489 - 5501 .
邵中一 , 罗敏 , 崔明超 , 等 . 野黄芩苷通过下调c-met逆转肺癌A549/DDP细胞顺铂耐药 [J]. 中国现代应用药学 , 2021 , 38 ( 4 ): 415 - 419 .
吴乾波 , 张敏 , 陶志华 . 欧前胡素通过下调c-met的表达提高肺癌CD133~+细胞亚群对吉非替尼的敏感性 [J]. 中国病理生理杂志 , 2017 , 33 ( 1 ): 46 - 52 .
路京 , 陈子龙 , 闵朕 , 等 . 紫草素逆转由肝细胞生长因子诱导的肺癌吉非替尼耐药 [J]. 中国病理生理杂志 , 2019 , 35 ( 1 ): 62 - 67 .
詹建伟 , 王剑 , 王弋 , 等 . 姜黄素逆转HGF诱导PC9细胞对吉非替尼的耐药 [J]. 中国病理生理杂志 , 2017 , 33 ( 5 ): 805 - 810 .
雷磊 , 梁静 , 刘鹏 , 等 . SU11274抑制人子宫内膜癌细胞增殖的分子机制 [J]. 现代肿瘤医学 , 2020 , 28 ( 7 ): 1081 - 1085 .
YAN X , LI P , ZHAN Y , et al . Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in non-small cell lung cancer cells harboring EGFR or RAS mutation [J]. Biochem Pharmacol , 2018 , 150 : 72 - 85 .
FUNG S , KNOEFEL W T , KRIEG A . Clinicopathological and prognostic significance of inhibitor of apoptosis protein (IAP) family members in lung cancer: A Meta-analysis [J]. Cancers (Basel) , 2021 , 13 ( 16 ): 4098 - 4121 .
PUSKAS R , BIKOV A , HORVATH P , et al . Circulating survivin protein levels in lung cancer patients treated with platinum-based chemotherapy [J]. Pathol Oncol Res , 2021 , 30 ( 27 ): 631969 .
WU X B , LI Q H , ZHANG N , et al . MiR-142 inhibits lung cancer cell proliferation and promotes apoptosis by targeting XIAP [J]. Eur Rev Med Pharmacol Sci , 2019 , 23 ( 17 ): 7430 - 7437 .
YU Y , JIN H , XU J , et al . XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDI β mRNA stability [J]. Int J Cancer , 2018 , 142 ( 10 ): 2040 - 2055 .
KIM S Y , PARK S , YOO S , et al . Downregulation of X-linked inhibitor of apoptosis protein by '7-benzylidenenaltrexone maleate' sensitizes pancreatic cancer cells to Trail-induced apoptosis [J]. Oncotarget , 2017 , 8 ( 37 ): 61057 - 61071 .
朱志阳 , 陈真伟 , 陈甸甸 , 等 . X连锁凋亡抑制蛋白和Krüppel样因子4在非小细胞肺癌组织的表达及其临床意义 [J]. 中华实验外科杂志 , 2020 , 37 ( 3 ): 555 - 557 .
YOO J K , LEE J M , KANG S H , et al . The novel microRNA hsa-miR-CHA1 regulates cell proliferation and apoptosis in human lung cancer by targeting XIAP [J]. Lung Cancer , 2019 , 132 : 99 - 106 .
CAO C , MU Y , HALLAHAN D E , et al . XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer [J]. Oncogene , 2004 , 23 ( 42 ): 7047 - 7052 .
SHIMIZU T , NISHIO K , SAKAI K , et al . Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer [J]. Cancer Chemother Pharmacol , 2020 , 86 ( 2 ): 211 - 219 .
WENTA T , RYCHLOWSKI M , JUREWICZ E , et al . The HtrA3 protease promotes drug-induced death of lung cancer cells by cleavage of the X-linked inhibitor of apoptosis protein (XIAP) [J]. FEBS J , 2019 , 286 ( 22 ): 4579 - 4596 .
戴月梅 , 哈依努尔 , 王晶 . 鸦胆子油乳对肺癌细胞A549的抑制作用及其机制 [J]. 中国临床药理学杂志 , 2018 , 34 ( 3 ): 288 - 290 .
王胜玫 , 刘炫均 , 邓桂明 , 等 . 雄黄纳米粒的制备及其靶向Survivin蛋白诱导A549细胞凋亡的研究 [J]. 中国药学杂志 , 2021 , 56 ( 7 ): 553 - 558 .
WU X B , LI Q H , ZHANG N , et al . MiR-142 inhibits lung cancer cell proliferation and promotes apoptosis by targeting XIAP [J]. Eur Rev Med Pharmacol Sci , 2019 , 23 ( 17 ): 7430 - 7437 .
YANG X P , LIU S L , XU J F , et al . Pancreatic stellate cells increase pancreatic cancer cells invasion through the hepatocyte growth factor /C-Met/survivin regulated by p53/p21 [J]. Exp Cell Res , 2017 , 357 ( 1 ): 79 - 87 .
HWANG S T , UM J Y , CHINNATHAMBI A , et al . Evodiamine mitigates cellular growth and promotes apoptosis by targeting the C-Met pathway in prostate cancer cells [J]. Molecules , 2020 , 25 ( 6 ): 1320 - 1333 .
BU R , UDDIN S , BAVI P , et al . HGF/C-Met pathway has a prominent role in mediating antiapoptotic signals through Akt in epithelial ovarian carcinoma [J]. Lab Invest , 2011 , 91 ( 1 ): 124 - 137 .
王江芬 , 王月玲 . HGF/Met传导通路在子宫内膜癌发生发展中的作用及意义 [J]. 中国现代医生 , 2015 , 53 ( 32 ): 1 - 7 .
0
Views
23
下载量
3
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution